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BACKGROUND
Pulmonary alveolar proteinosis is a disease characterized by abnormal accumula-
tion of surfactant in the alveoli. Most cases are autoimmune and are associated 
with an autoantibody against granulocyte–macrophage colony-stimulating factor 
(GM-CSF) that prevents clearing of pulmonary surfactant by alveolar macrophages. 
An open-label, phase 2 study showed some therapeutic efficacy of inhaled recom-
binant human GM-CSF in patients with severe pulmonary alveolar proteinosis; 
however, the efficacy in patients with mild-to-moderate disease remains unclear.
METHODS
We conducted a double-blind, placebo-controlled trial of daily inhaled recombi-
nant human GM-CSF (sargramostim), at a dose of 125 μg twice daily for 7 days, 
every other week for 24 weeks, or placebo in 64 patients with autoimmune pulmo-
nary alveolar proteinosis who had a partial pressure of arterial oxygen (Pao2) while 
breathing ambient air of less than 70 mm Hg (or <75 mm Hg in symptomatic 
patients). Patients with severe pulmonary alveolar proteinosis (Pao2 <50 mm Hg) 
were excluded to avoid possible exacerbation of the disease in patients who were 
assigned to receive placebo. The primary end point was the change in the alveolar–
arterial oxygen gradient between baseline and week 25.
RESULTS
The change in the mean (±SD) alveolar–arterial oxygen gradient was significantly 
better in the GM-CSF group (33 patients) than in the placebo group (30 patients) 
(mean change from baseline, −4.50±9.03 mm Hg vs. 0.17±10.50 mm Hg; P = 0.02). 
The change between baseline and week 25 in the density of the lung field on 
computed tomography was also better in the GM-CSF group (between-group dif-
ference, −36.08 Hounsfield units; 95% confidence interval, −61.58 to −6.99, calcu-
lated with the use of the Mann–Whitney U test and the Hodges–Lehmann estimate 
of confidence intervals for pseudo-medians). Serious adverse events developed in 
6 patients in the GM-CSF group and in 3 patients in the placebo group.
CONCLUSIONS
In this randomized, controlled trial, inhaled recombinant human GM-CSF was 
associated with a modest salutary effect on the laboratory outcome of arterial 
oxygen tension, and no clinical benefits were noted. (Funded by the Japan Agency 
for Medical Research and Development and the Ministry of Health, Labor, and 
Welfare of Japan; PAGE ClinicalTrials.gov number, NCT02835742; Japan Medical 
Association Center for Clinical Trials number, JMA-IIA00205.)
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Pulmonary alveolar proteinosis, an uncommon lung disease characterized by the accumulation of pulmonary surfactant 
within pulmonary alveoli, causes progressive respi-
ratory insufficiency.1,2 Approximately 90% of cases 
of pulmonary alveolar proteinosis are autoimmune; 
autoimmune pulmonary alveolar proteinosis is as-
sociated with a high level of autoantibodies against 
granulocyte–macrophage colony-stimulating factor 
(GM-CSF).3 These autoantibodies, which neutral-
ize the biologic activity of GM-CSF,4 impair the 
clearance of surfactant and lead to the disease.5-10
Pulmonary alveolar proteinosis is commonly 
treated with whole-lung lavage11 while the patient 
is under general anesthesia. In this procedure, 
each lung is infused with up to 50 liters of saline 
to physically remove the surfactant sediment. 
Although this treatment improves lung function 
in most patients,12 repeated treatments are usu-
ally required because of the reaccumulation of 
surfactant.13 Some improvement in pulmonary 
function has been observed in trials of subcuta-
neous recombinant human GM-CSF involving 
patients with pulmonary alveolar proteinosis.14-16
In one study involving GM-CSF knockout mice, 
inhalation (but not extrapulmonary delivery) of 
GM-CSF corrected pulmonary alveolar proteino-
sis.17 By analogy, inhalation of aerosolized exog-
enous GM-CSF could benefit patients with auto-
immune pulmonary alveolar proteinosis. Pilot 
studies and a prospective multicenter, open-label, 
phase 2 study of inhaled GM-CSF therapy showed 
improvements in gas exchange, especially in pa-
tients with severe pulmonary alveolar proteinosis, 
with no serious treatment-related side effects.18-21 
However, these results may be affected by spon-
taneous remission, which occurs in approximately 
20% of patients with pulmonary alveolar proteino-
sis.13 Moreover, the efficacy of inhaled GM-CSF 
in patients with mild-to-moderate disease remains 
unknown. We conducted the Pulmonary Alveolar 
Proteinosis GM-CSF Inhalation Efficacy (PAGE) 
trial, a multicenter, randomized, controlled trial, 
to test the hypothesis that inhaled GM-CSF would 
improve oxygenation, findings on lung imaging, 
and levels of serum markers in patients with mild-
to-moderate pulmonary alveolar proteinosis.
Me thods
Trial Design and Oversight
The trial was designed by the investigators of the 
PAGE Trial Study Group at the Niigata University 
Medical and Dental Hospital and at 11 other 
hospitals in Japan. The trial was approved by the 
institutional review board of each participating 
hospital and conducted by the clinical trial coor-
dinating committee. Data were collected from 
case-report forms in an electronic data-capture 
system and submitted to the Clinical and Trans-
lational Research Center (CTRC) at the Niigata 
University Medical and Dental Hospital. The 
CTRC members (listed in the Supplementary 
Appendix, available with the full text of this 
article at NEJM.org) analyzed the data, and the 
authors who are members of the CTRC vouch 
for the accuracy and completeness of the data 
and analyses and for adherence of the trial to 
the protocol, available at NEJM.org. All the au-
thors participated in writing the manuscript and 
made the decision to submit the manuscript for 
publication.
Patient Recruitment
Patients with pulmonary alveolar proteinosis 
were identified from questionnaires completed 
by chief pulmonologists at major hospitals 
throughout Japan. These surveys were based on 
the laboratory records of patients who had un-
dergone testing to detect autoantibodies against 
GM-CSF.
Patients were eligible to participate in the 
trial if they were between 16 and 80 years of age; 
had received a diagnosis of autoimmune pulmo-
nary alveolar proteinosis on the basis of find-
ings on high-resolution computed tomography 
(CT) and biopsy, cytologic findings on broncho-
alveolar lavage, or both; had a positive serum 
GM-CSF antibody level (>1.0 μg per milliliter)22; 
and had a partial pressure of arterial oxygen 
(Pao2) of less than 70 mm Hg after 5 minutes in 
the supine position while breathing ambient air, 
or less than 75 mm Hg and at least one of the 
following symptoms: cough, sputum production, 
or exertional dyspnea.
The exclusion criteria included lung-lavage 
therapy within the previous 6 months, previous 
GM-CSF or other cytokine therapy, or current or 
planned pregnancy. Patients with a Pao2 of less 
than 50 mm Hg while breathing ambient air 
were excluded. All the patients provided written 
informed consent with documents approved by 
the institutional review board of each participat-
ing hospital. Further details on the inclusion and 
exclusion criteria are provided in Section 2 in the 
Supplementary Appendix.
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Randomization
Patients who met the eligibility criteria were 
randomly assigned by computer, in a 1:1 ratio, 
to receive either inhaled GM-CSF (at a dose of 
125 μg twice daily on days 1 through 7 and 
none on days 8 through 14 for 12 2-week cycles) 
or matched placebo. All the patients and phy-
sicians in charge were unaware of the trial-
group assignments during the 24-week inter-
vention period. Details regarding randomization 
are provided in Section 3 in the Supplementary 
Appendix.
Trial Agents and Procedure
The recombinant human GM-CSF (sargramostim, 
lyophilized formulation) and placebo were pro-
vided and delivered to Japan free of charge by 
Sanofi Genzyme, which had no role in the de-
sign or execution of the trial or in the analyses 
or reporting of the data. Both GM-CSF and pla-
cebo were inhaled, as described previously.19-21,23 
Adverse events were assessed according to the 
National Cancer Institute Common Terminology 
Criteria for Adverse Events.24 Laboratory tests to 
assess patient safety included hematologic, serum, 
and urinary tests.
Trial End Points
The primary end point was the change in the 
alveolar–arterial oxygen gradient between base-
line and week 25, as described previously.19,20 This 
end point was compared between the GM-CSF 
group and the placebo group. Detailed methods 
of arterial blood gas analyses and calculations of 
the alveolar–arterial oxygen gradient used in this 
trial are provided in Section 3 in the Supplemen-
tary Appendix.
Efficacy was also evaluated with respect to 
the following secondary end-point measures: 
symptoms (cough, sputum production, and ex-
ertional dyspnea); the score on the modified 
Medical Research Council Dyspnea Scale (scores 
range from 0 to 4, with higher scores indicating 
worse respiratory status); vital capacity; diffusion 
capacity of the lung for carbon monoxide (DLco); 
Pao2 while the patient was breathing ambient 
air; distance walked in a 6-minute walk test; 
findings on chest high-resolution CT; serum 
levels of mucinlike glycoprotein KL-6, carcino-
embryonic antigen, surfactant protein D, surfac-
tant protein A, high-sensitivity C-reactive protein, 
monocyte chemotactic protein 1 (MCP-1), and 
autoantibodies against GM-CSF; and scores on 
the chronic obstructive pulmonary disease (COPD) 
assessment test questionnaire (scores range from 
0 to 40, with higher scores indicating a more 
severe effect on a patient’s quality of life). Trial 
visits occurred at screening, baseline, and at 
weeks 7, 13, 19, 25, 31, 37, and 43.
Chest high-resolution CT scans were evaluat-
ed with CT densitometry techniques25 that were 
modified for the Synapse Vincent volume ana-
lyzer (Fujifilm); this analyzer was used instead 
of a visual scoring system.21 The analyzer calcu-
lated a density value of the lung field on CT from 
density signals (Hounsfield units) and pixel 
numbers for each image slice, and the mean CT 
density values were calculated for each patient.
Primary and secondary end points were mea-
sured at baseline and during every visit, as de-
scribed in the trial calendar in Section 4 in the 
Supplementary Appendix. Furthermore, we con-
ducted univariate and multivariate analyses of 
the relationship between the clinical characteris-
tics at baseline and the change in the alveolar–
arterial oxygen gradient as a prespecified sub-
group analysis.
Statistical Analysis
The sample size was calculated with the use of 
a two-tailed t-test. For the primary analysis, we 
determined that a sample size of 30 patients in 
each group (for a total of 60 patients) would 
provide the trial with a power of 80% to detect 
an effect size of 1.31 (95% confidence interval 
[CI], 0.76 to 1.81) at the 5% significance level 
in the change from baseline to week 25 in the 
alveolar–arterial oxygen gradient between the 
GM-CSF group and the placebo group. This cal-
culation was based on Cohen’s d formula (the 
difference of means divided by the pooled stan-
dard deviation).
Numerical results are presented as means 
(±SD) or medians with interquartile ranges. 
Analyses were performed according to the inten-
tion-to-treat principle. The Mann–Whitney U 
test was used to assess the difference between 
the two groups, and the sign test was used to 
assess the differences from baseline to week 25 
within each group. A linear mixed-effects model 
and a generalized linear model were used to 
evaluate differences between and within groups. 
The model included the time elapsed since en-
rollment, treatment assignment, and interaction 
between time and treatment. The model proce-
dure using statistics with the Kenward–Roger 
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adjustment method was used to fit the model 
without imputation of missing data. For categor-
ical end points, the data were compared with the 
use of either the chi-square test or Fisher’s exact 
test. For continuous variables, the medians were 
compared with a Mann–Whitney U test. The P 
value was two-sided and used for the primary 
end point only. A P value of less than 0.05 was 
considered to indicate statistical significance.
We used the linear mixed-effects model to 
evaluate the interaction of treatment with smok-
ing history, with the alveolar–arterial oxygen 
gradient as the dependent variable. The model 
included the time elapsed since enrollment (in 
months), the treatment assignment (GM-CSF or 
placebo), smoking history (in persons who had 
never smoked vs. current smokers or former 
smokers), and the interaction among time, treat-
ment, and smoking history. Estimates of the 
effects obtained from the full model used in the 
analysis are shown in Table S4 in the Supple-
mentary Appendix. All analyses were performed 
with the use of SAS software, version 9.4 (SAS 
Institute).
R esult s
Patients
From September 2016 through December 2016, 
a total of 78 patients were assessed for eligibility 
(Fig. 1). Of these patients, 64 patients with mild-
to-moderate autoimmune pulmonary alveolar pro-
teinosis were deemed to be eligible to participate 
in the trial and were randomly assigned to either 
the GM-CSF group (33 patients) or the placebo 
group (31 patients) (Table 1, and Table S1 in the 
Supplementary Appendix). One patient assigned 
to the placebo group withdrew from the trial, 
and a total of 63 patients completed the 24-week 
double-blind intervention period.
Primary End Point
The change in the alveolar–arterial oxygen gra-
dient was significantly greater in the GM-CSF 
Figure 1. Screening, Randomization, and Follow-up.
During the 24-week randomized, double-blind, placebo-controlled trial, all the patients remained unaware of their 
trial-group assignments. An analysis of arterial blood gas was performed every 12 weeks. Of the 78 patients with 
pulmonary alveolar proteinosis who underwent screening, 64 were enrolled and 63 completed the trial. One patient 
in the placebo group withdrew from the trial because of anxiety caused by rapidly progressing autoimmune pulmo-
nary alveolar proteinosis. GM-CSF denotes granulocyte–macrophage colony-stimulating factor.
64 Underwent randomization
78 Patients were assessed for eligibility
14 Were ineligible
33 Were assigned to receive
recombinant human GM-CSF
31 Were assigned to receive placebo
1 Withdrew from the trial
33 Had data available at wk 13
and wk 25 visits
30 Had data available at wk 13
and wk 25 visits
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Variable
GM-CSF Group 
 (N = 33)
Placebo Group 
 (N = 31)
Age — yr 56.5±12.4 57.2±12.9
Female sex — no. (%) 14 (42) 13 (42)
Tobacco use — no. (%)
Current smoker 3 (9) 1 (3)
Former smoker 12 (36) 18 (58)
Never smoked 18 (55) 12 (39)
Dust exposure — no. (%) 13 (39) 14 (45)
Symptom score on modified Medical Research Council Dyspnea 
Scale†
1.55±0.94 1.42±0.96
Total COPD assessment test score‡ 13.5±8.52 14.5±7.95
Density of lung field on CT
No. of patients with data 31 28
Value — Hounsfield units −664.2±95.07 −676.9±88.02
Results of pulmonary-function tests
Percentage of predicted vital capacity 77.2±17.6 82.3±14.9
DLco
No. of patients with data 32 30
Percentage of predicted value 64.7±22.1 64.1±19.5
Pao2 — mm Hg§ 66.4±8.66 68.8±8.96
Alveolar–arterial oxygen gradient — mm Hg¶ 37.5±9.99 35.2±11.4
Serum markers
Mucinlike glycoprotein KL-6 — U/ml 5264±3102 8104±10345
Carcinoembryonic antigen — ng/ml 7.95±6.36 8.34±7.28
Surfactant protein D — ng/ml 271.8±187.7 344.1±236.1
Surfactant protein A — ng/ml 107.2±53.8 128.4±112.1
High-sensitivity C-reactive protein — ng/ml 600.9±697.0 1087±2515
MCP-1
No. of patients with data 33 30
Value — pg/ml 410.5±137.6 415.2±149.5
Autoantibodies against GM-CSF — μg/ml 66.8±71.7 61.8±53.5
*  Plus–minus values are means ±SD. COPD denotes chronic obstructive pulmonary disease, CT computed tomography, 
DLco diffusion capacity of the lung for carbon monoxide, GM-CSF granulocyte–macrophage colony-stimulating factor, 
and MCP-1 monocyte chemotactic protein 1.
†  Scores on the Medical Research Council Dyspnea Scale range from 0 to 4, with higher scores indicating worse respira-
tory status.
‡  Total COPD assessment test scores range from 0 to 40, with higher scores indicating a more severe effect on a patient’s 
quality of life.
§  The partial pressure of alveolar oxygen (Pao2) is measured while the patient is in a supine position and breathing am-
bient air.
¶  The alveolar–arterial oxygen gradient is calculated with the use of the following equation: alveolar–arterial oxygen gradient  
= (PB − PH20) × Fio2 − Paco2/R + {Paco2 × Fio2 × (1 − R)/R} − Pao2, where Fio2 indicates fraction of inspired oxygen, Paco2 
partial pressure of arterial carbon dioxide, PB barometric pressure measured by validated barometers, PH20 partial pres-
sure of water vapor in inspired air (assumed to be 47 mm Hg), and R the respiratory exchange ratio (assumed to be 0.8).
Table 1. Clinical Characteristics of the Patients at Baseline.*
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group than in the placebo group (mean [±SD] 
change from baseline, −4.50±9.03 mm Hg vs. 
0.17±10.50 mm Hg; P = 0.02) (Fig. 2A and Table 2). 
The greater decrease in the alveolar–arterial oxy-
gen gradient in the GM-CSF group was driven by 
the higher Pao2 in that group than in the placebo 
group (4.77±9.43 mm Hg vs. –0.05±9.48 mm Hg; 
difference vs. placebo, 5.40; 95% CI, 1.00 to 9.90).
 Secondary and Exploratory End Points
Scores on the COPD assessment test did not dif-
fer substantially between the groups (Table 2); 
the change in the score on the modified MRC 
Dyspnea Scale differed between the groups (inter-
action between time and treatment per month, 
0.07; 95% CI, 0.01 to 0.13, as assessed by means 
of a linear mixed-effects model).
CT values for radiographic density were avail-
able for 31 of 33 patients in the GM-CSF group 
and 28 of 30 patients in the placebo group, and 
these values were used in statistical analyses. 
The change in CT density values between base-
line and week 25 was −22.4 in the GM-CSF 
group and −2.5 in the placebo group, for a pseudo-
median between-group difference of −36.08 (95% 
CI, −61.58 to −6.99, calculated with the use of 
the Mann–Whitney U test and the Hodges–
Lehmann estimate of confidence intervals for 
pseudo-medians) (Table 2 and Fig. 2B). Similar-
ly, the slope of the change in CT density between 
baseline and week 25 in the GM-CSF group was 
steeper than that in the placebo group (inter-
action between time and treatment per month, 
3.27; 95% CI, 1.80 to 4.73, as assessed by means 
of a linear mixed-effects model).
We conducted seven statistical tests of hypoth-
eses to compare the trial groups with respect to 
changes in serum levels of biomarkers, including 
KL-6, MCP-1, carcinoembryonic antigen, surfac-
tant protein D, surfactant protein A, high-sensitiv-
ity C-reactive protein, and autoantibodies against 
GM-CSF. The changes in the levels of KL-6 between 
baseline and week 25 were −1199±3098 U per 
milliliter in the GM-CSF group and 4.70±9154 U 
per milliliter in the placebo group (Table 2). This 
finding suggests that GM-CSF was effective (esti-
mated difference, −0.92; 95% CI, −0.94 to −0.90, 
as assessed by means of a generalized linear 
model); this finding was consistent with the re-
sults of a previous study.21 In addition, the change 
from baseline in serum levels of MCP-1, a small 
cytokine that recruits monocytes, was greater in 
patients in the GM-CSF group than in patients in 
the placebo group (−36.1±91.5 pg per milliliter 
vs. 17.0±102.4 pg per milliliter; pseudo-median 
between-group difference, −58.45 pg per milli-
liter [95% CI, −97.49 to −17.51], as assessed by 
means of a Mann–Whitney U test) (Table 2).
Vital capacity did not significantly improve in 
either group between baseline and week 25, with 
a mean change of 1.89±6.24% in the GM-CSF 
group and −0.74±7.42% in the placebo group, for 
a pseudo-median between-group difference of 
3.31 percentage points (95% CI, −0.59 to 6.35). 
Figure 2. Changes in the Alveolar–Arterial Oxygen Gradient.
Panel A shows changes in the alveolar–arterial oxygen gradient from baseline 
to week 25 in the GM-CSF group (33 patients) and placebo group (30 patients) 
during the 24-week randomized intervention period. The middle solid hori-
zontal lines show the median values, the upper solid horizontal lines show 
the 75th percentiles, and the lower solid horizontal lines show the 25th per-
centiles. Each circle represents an individual patient. Panel B shows high-
resolution computed tomographic (CT) images of the chest in a represen-
tative patient from the GM-CSF group at baseline and at week 25, with a 
reduction in ground-glass opacity during treatment. The distribution of num-
bers of pixels with various CT density values for the same patient is shown.
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The change in the percentage of predicted DLco 
from baseline to week 25 was 4.70±15.57 in the 
GM-CSF group and 0.37±14.46 in the placebo 
group, for a pseudo-median between-group dif-
ference of 6.87 (95% CI, 0.62 to 13.05, as as-
sessed by means of a Mann–Whitney U test) 
(Table 2).
The mean distance on the 6-minute walk test 
in both groups at baseline was greater than 360 m; 
this indicates that most patients were able to en-
gage in mild exercise. There was no substantial 
difference in the change in walking distance 
between baseline and week 25 in the GM-CSF 
group and the placebo group (19.19±71.80 m vs. 
5.63±178.57 m, for a pseudo-median between-
group difference of 1.52 m [95% CI, −42.00 to 
50.00]) (Table 2).
Efficacy in Current and Former Smokers
We created an expanded linear mixed-effects 
model with all the variables including time, 
treatment, smoking history, and the two-way 
and three-way interactions of time, treatment, and 
smoking history, as well as trial site, symptom, 
disease severity, sex, age, dust exposure, and pre-
vious whole-lung lavage. This model was used to 
assess the interactions of background variables 
with the change in the alveolar–arterial oxygen 
gradient from baseline to week 25 (Table S4 in 
the Supplementary Appendix). The results of this 
analysis indicated that there was a minimal ef-
fect of inhaled GM-CSF in patients who were 
smokers.
Autoantibodies against GM-CSF
It is notable that the change in the level of auto-
antibodies against GM-CSF was greater in the 
GM-CSF group than in the placebo group 
(8.58±24.94 μg per milliliter vs. −4.88±10.36 μg 
per milliliter, for a pseudo-median difference of 
10.75 [95% CI, 1.70 to 17.05]). This finding sug-
gests that inhaled GM-CSF accelerated produc-
tion of these autoantibodies (Fig. S2A in the Sup-
plementary Appendix). The neutralizing capacity 
of the GM-CSF antibody did not change signifi-
cantly in the GM-CSF group during the trial (Fig. 
S2B in the Supplementary Appendix).
Adverse Events
No deaths occurred during the trial. Adverse 
events that occurred during the trial did not dif-
fer significantly between the two groups (Table 
S2 in the Supplementary Appendix). Serious ad-
verse events occurred in 6 of the 33 patients who 
received GM-CSF. These events were ileus, con-
gestive heart failure, worsening of autoimmune 
pulmonary alveolar proteinosis, pneumothorax, 
influenza type A infection, lacunar infarction, 
and breast cancer; 1 patient had both influenza 
type A infection and worsening of autoimmune 
pulmonary alveolar proteinosis. Three of the 31 
patients who received placebo also reported seri-
ous adverse events during the trial; these events 
were cataract, worsening of autoimmune pulmo-
nary alveolar proteinosis, and peripheral sensory 
neuropathy.
Discussion
In this randomized, controlled trial involving 
patients with mild-to-moderate autoimmune pul-
monary alveolar proteinosis, the change in the 
alveolar–arterial oxygen gradient was better with 
inhaled GM-CSF than with placebo. The effect 
of spontaneous remission, which occurs in ap-
proximately 20% of patients, and the placebo 
effect may have played a role in the earlier open-
label phase 2 study. The effects of spontaneous 
remission on the reduction in symptoms of pul-
monary alveolar proteinosis were obviated by the 
present randomized trial design.
Effects were observed on laboratory rather 
than clinical measures. This outcome may be a 
result of the exclusion of patients with the most 
severe cases to prevent exacerbation of the con-
dition if they received placebo for 24 weeks. In 
the previous phase 2 study,21 patients with severe 
autoimmune pulmonary alveolar proteinosis had 
a response to inhaled GM-CSF, and the exclusion 
of these patients from this trial may explain the 
rather modest effects on the alveolar–arterial 
oxygen gradient in the GM-CSF group and the 
modest between-group difference in symptoms as 
measured by the score on the COPD assessment 
test or 6-minute walk test. Since the primary and 
secondary end-point measures in the GM-CSF 
group changed together in parallel (although 
some changes were small), the data across mul-
tiple end-point measures indicated, at best, a 
modest therapeutic benefit.
The difference between current or former 
smokers and patients who had never smoked 
with respect to the increase in the alveolar–arterial 
oxygen gradient suggests that cigarette smoking 
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may affect the pathway of antibody production 
and thus stimulate GM-CSF neutralization. We 
speculate that long-term cigarette smoking may 
cause minimal remodeling of small airways, 
leading to changes in mucus production that 
affect the distribution of inhaled GM-CSF in the 
lung. In addition, alveolar macrophages in smok-
ers may be functionally impaired beyond the 
defects caused by GM-CSF autoantibodies; this 
impairment may be responsible for the poor 
response to inhaled GM-CSF in smokers with 
autoimmune pulmonary alveolar proteinosis.
During the trial, we observed an increase in 
serum levels of autoantibodies against GM-CSF 
in the GM-CSF group but not in the placebo 
group. However, the neutralizing capacity did 
not differ between the groups, probably because 
of the duration of inhalation. Administration of 
subcutaneous, long-term, intermittent recombi-
nant human GM-CSF can cause a transient induc-
tion of autoantibodies against GM-CSF in patients 
with metastatic colon cancer26 and, in some pa-
tients, the antibody can be neutralizing.27 Infu-
sion of yeast-derived GM-CSF has also induced 
GM-CSF–reactive autoantibodies in patients with 
cancer.28 Because of the lack of a placebo group, 
the previous phase 2 study could not show an in-
crease in levels of autoantibodies against GM-CSF 
in patients who received GM-CSF; this finding 
may have been associated with the production 
of autoantibodies against the extrinsic, inhaled 
GM-CSF.
This trial has some limitations. First, only one 
dose of GM-CSF was tested. The effect of higher 
doses is not known but could be a basis for fur-
ther research. Second, only one type of nebu-
lizer was used for inhalation therapy. Although 
jet nebulizers are inexpensive and commonly 
used, nebulizers with newer vibrating mesh or 
membrane components, which are more efficient 
and facilitate shorter treatment times, could be 
evaluated. Third, the lyophilized formulation 
of recombinant human GM-CSF that was used 
in this trial required patients to dissolve the agent 
in saline before inhalation. Face-to-face instruc-
tion and a brochure and video instructions for 
home reference are needed. It is possible that a 
liquid formulation of GM-CSF would make ad-
ministration simpler.
The results of our randomized, controlled trial 
showed that inhaled GM-CSF had a significant 
but very modest effect on the alveolar–arterial 
oxygen gradient in patients with pulmonary al-
veolar proteinosis. At the dose used, there were 
changes in some laboratory measures, but no 
clinically important changes in outcomes were 
noted.
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